` HIGHLIGHTS OF PRESCRIBING INFORMATION
` These highlights do not include all the information needed to use
`
`
`
`
`
` RAPAMUNE safely and effectively. See full prescribing information for
` RAPAMUNE.
`
`
` RAPAMUNE (sirolimus) oral solution
`
`
` RAPAMUNE (sirolimus) tablets, for oral use
`
` Initial U.S. Approval: 1999
`
`
`
`
`
`•
`
` WARNING: IMMUNOSUPPRESSION, USE IS NOT
`
`RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS
`
`
` See full prescribing information for complete boxed warning.
`
`
`
`
`
` Increased susceptibility to infection and the possible development
`
`
`
`
` of lymphoma and other malignancies may result from
` immunosuppression (5.1). Only physicians experienced in
`
`
`
`
` immunosuppressive therapy and management of renal transplant
`
` patients should use Rapamune for prophylaxis of organ rejection
`
`
` in patients receiving renal transplants.
`
`
`
` • The safety and efficacy of Rapamune as immunosuppressive
`
`
` therapy have not been established in liver or lung transplant
`
`
`
` patients, and therefore, such use is not recommended (5.2, 5.3).
`
`
`
` − Liver Transplantation – Excess mortality, graft loss, and
`
`
`
`
`
` hepatic artery thrombosis (5.2).
`
`
`
` − Lung Transplantation – Bronchial anastomotic dehiscence (5.3).
`
`
`
`
`
`
`
`
`
`o
`
`
`
`
`
`
`--------------------------- RECENT MAJOR CHANGES-------------------------
`
`
`
`
`
`
`Warnings and Precautions, Cannabidiol Drug Interactions (5.21)
`8/2022
`
`
`------------------------------INDICATIONS AND USAGE-----------------------
`
`
`
`
`
`
`
`• Rapamune is an mTOR inhibitor immunosuppressant indicated for the
`
`
`
`
`
`
`
`
`
`
`prophylaxis of organ rejection in patients aged ≥13 years receiving
`
`renal transplants:
`
`
`
`Patients at low- to moderate-immunologic risk: Use initially with
`o
`
`
`cyclosporine (CsA) and corticosteroids. CsA withdrawal is
`
`
`recommended 2-4 months after transplantation (1.1).
`
`
`
`Patients at high-immunologic risk: Use in combination with CsA
`
`
`
`and corticosteroids for the first 12 months following
`
`
`transplantation (1.1). Safety and efficacy of CsA withdrawal has
`
`
`
`
`
`
`
`
`
`
`not been established in high risk patients (1.1, 1.2, 14.3).
`
`
`
`
`
`
`
`• Rapamune is an mTOR inhibitor indicated for the treatment of
`
`
`patients with lymphangioleiomyomatosis (1.3).
`
`
`-------------------------DOSAGE AND ADMINISTRATION-------------------
`
`
`
`Renal Transplant Patients:
`
`
`
`
`
`
`• Administer once daily by mouth, consistently with or without food (2).
`
`
`
`
`
`
`• Administer the initial dose as soon as possible after
`
`
`transplantation and 4 hours after CsA (2.1, 7.1).
`
`
`
`
`
`• Adjust the Rapamune maintenance dose to achieve sirolimus
`
`
`trough concentrations within the target-range (2.5).
`
`
`
`
`
`• Hepatic impairment: Reduce maintenance dose in patients
`
`
`
`with hepatic impairment (2.7, 8.6, 12.3).
`
`In renal transplant patients at low-to moderate-immunologic risk:
`
`
`
`
`
`
`
`
`
`
`• Rapamune and CsA Combination Therapy: One loading dose of 6 mg on
`
`
`
`
`day 1, followed by daily maintenance doses of 2 mg (2.2).
`
`
`
`
`
`• Rapamune Following CsA Withdrawal: 2-4 months post-transplantation,
`
`
`
`withdraw CsA over 4-8 weeks (2.2).
`
`
`
`In renal transplant patients at high-immunologic risk:
`
`
`
`
`
`• Rapamune and CsA Combination Therapy (for the first 12 months post-
`
`
`
`
`
`
`
`
`transplantation): One loading dose of up to 15 mg on day 1, followed by
`
`
`
`
`daily maintenance doses of 5 mg (2.3).
`
`
`
`
`Reference ID: 5033875
`
`1
`
`
`
`
`
`
`
`
`
`Lymphangioleiomyomatosis Patients:
`
`
`
`
`
`
`• Administer once daily by mouth, consistently with or without food (2).
`
`
`
`
`
`
`• Recommended initial Rapamune dose is 2 mg/day (2.4).
`
`
`
`
`
`
`
`• Adjust the Rapamune dose to achieve sirolimus trough concentrations
`
`
`
`between 5-15 ng/mL (2.4).
`
`
`
`
`• Hepatic impairment: Reduce maintenance dose in patients with hepatic
`
`
`impairment (2.7, 8.6, 12.3).
`
`
`
`Therapeutic drug monitoring is recommended for all patients (2.5, 5.17).
`
`---------------------DOSAGE FORMS AND STRENGTHS--------------------
`
`
`
`
`
`
`
`
`• Oral Solution: 60 mg per 60 mL in amber glass bottle (3.1).
`
`
`
`
`
`
`• Tablets: 0.5 mg, 1 mg, 2 mg (3.2).
`
`
`-----------------------------CONTRAINDICATIONS------------------------------
`
`
`
`
`Hypersensitivity to Rapamune (4).
`
`------------------------WARNINGS AND PRECAUTIONS---------------------
`
`
`
`
`• Hypersensitivity Reactions (5.4)
`
`
`
`• Angioedema (5.5)
`
`
`
`
`
`
`• Fluid Accumulation and Impairment of Wound Healing (5.6)
`
`
`
`• Hyperlipidemia (5.7)
`
`
`
`
`• Decline in Renal Function (5.8)
`
`
`
`• Proteinuria (5.9)
`
`
`
`• Latent Viral Infections (5.10)
`
`
`
`
`Interstitial Lung Disease/Non-Infectious Pneumonitis (5.11)
`•
`
`
`
`
`• De Novo Use Without Cyclosporine (5.12)
`
`
`
`
`
`Increased Risk of Calcineurin Inhibitor-Induced Hemolytic Uremic
`•
`
`
`Syndrome/ Thrombotic Thrombocytopenic Purpura/ Thrombotic
`
`
`Microangiopathy (5.13)
`
`
`
`
`• Embryo-Fetal Toxicity: Can cause fetal harm. Use of highly effective
`
`contraception is recommended for females of reproductive potential
`
`
`
`during treatment and for 12 weeks after final dose of Rapamune (5.15,
`
`8.1)
`
`
`
`
`
`
`
`
`• Male Infertility: Azoospermia or oligospermia may occur (5.16, 13.1)
`
`
`
`
`
`
`Immunizations: Avoid live vaccines (5.19)
`•
`
`
`------------------------------ADVERSE REACTIONS-----------------------------
`
`
`
`
`Prophylaxis of organ rejection in patients receiving renal transplants: Most
`
`common adverse reactions (incidence ≥30%) are peripheral edema,
`
`
`hypertriglyceridemia, hypertension, hypercholesterolemia, creatinine
`
`
`
`increased, abdominal pain, diarrhea, headache, fever, urinary tract infection,
`
`
`anemia, nausea, arthralgia, pain, and thrombocytopenia (6).
`
`
`
`
`
`
`
`Lymphangioleiomyomatosis: Most common adverse reactions (incidence
`
`
`
`
`≥20%) are stomatitis, diarrhea, abdominal pain, nausea, nasopharyngitis,
`
`acne, chest pain, peripheral edema, upper respiratory tract infection,
`
`
`
`
`headache, dizziness, myalgia, and hypercholesterolemia (6.6).
`
`
`To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc.
`
`
`
`at 1-800-438-1985 or FDA at 1-800-FDA-1088 or
`
`www.fda.gov/medwatch.
`
`----------------------------DRUG INTERACTIONS-------------------------------
`
`
`
`
`
`
`
`
`• Avoid concomitant use with strong CYP3A4/P-gp inducers or strong
`
`
`CYP3A4/P-gp inhibitors that decrease or increase sirolimus
`
`
`
`concentrations (7.4, 12.3).
`
`
`
`
`
`
`• Therapeutic drug monitoring and dose reduction for Rapamune should
`
`be considered when Rapamune is co-administered with cannabidiol
`
`(5.21, 7.5).
`
`
`
`
`
`• See full prescribing information for complete list of clinically significant
`
`
`
`drug interactions (12.3).
`
`
`------------------------USE IN SPECIFIC POPULATIONS---------------------
`
`
`
`
`
`
`
`• Pregnancy: Based on animal data can cause fetal harm (5.15, 8.1).
`
`
`
`
`
`
`• Lactation: Potential for serious adverse effects in breastfed infants
`
`
`
`based on mechanism of action (8.2).
`
`
`
`
`
`• Females and Males of Reproductive Potential: May impair fertility (8.1.
`
`8.3, 13.1).
`
`
`
`See 17 for PATIENT COUNSELING INFORMATION and the
`
`FDA-approved Medication Guide
`
`
`
`Revised: 8/2022
`
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 6.2 Rapamune Following Cyclosporine Withdrawal
`
`
` 6.3 High-Immunologic Risk Renal Transplant Patients
`
`
`
` 6.4 Conversion from Calcineurin Inhibitors to Rapamune in
`
` Maintenance Renal Transplant Population
`
`
` 6.5 Pediatric Renal Transplant Patients
`
`
`
`
` 6.6 Patients with Lymphangioleiomyomatosis
`
` 6.7 Postmarketing Experience
`
` 7 DRUG INTERACTIONS
`
`
`
` 7.1 Use with Cyclosporine
`
`
`
` 7.2 Strong Inducers and Strong Inhibitors of CYP3A4 and P-gp
`
`
`
` 7.3 Grapefruit Juice
`
`
` 7.4 Weak and Moderate Inducers or Inhibitors of CYP3A4 and P-gp
`
`
` 7.5 Cannabidiol
`
` 8 USE IN SPECIFIC POPULATIONS
`
`
` 8.1 Pregnancy
`
` 8.2 Lactation
`
`
` 8.3 Females and Males of Reproductive Potential
`
` 8.4 Pediatric Use
`
`
`
` 8.5 Geriatric Use
`
`
` 8.6 Patients with Hepatic Impairment
`
` 8.7 Patients with Renal Impairment
`
`
` 10 OVERDOSAGE
`
`
`
`
` 11 DESCRIPTION
`
` 12 CLINICAL PHARMACOLOGY
`
`
`
` 12.1 Mechanism of Action
`
` 12.2 Pharmacodynamics
`
`
` 12.3 Pharmacokinetics
`
`
` 13 NONCLINICAL TOXICOLOGY
`
` 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`
` 14 CLINICAL STUDIES
`
`
`
`
`
` 14.1 Prophylaxis of Organ Rejection in Renal Transplant Patients
`
`
`
`
` 14.2 Cyclosporine Withdrawal Study in Renal Transplant Patients
`
` 14.3 High-Immunologic Risk Renal Transplant Patients
`
`
`
`
`
`
`14.4 Conversion from Calcineurin Inhibitors to Rapamune in
`
`
`Maintenance Renal Transplant Patients
`
`
`
`14.5 Conversion from a CNI-based Regimen to a Sirolimus-based
`
`Regimen in Liver Transplant Patients
`
`
`
`14.6 Pediatric Renal Transplant Patients
`
`
`14.7 Lymphangioleiomyomatosis Patients
`
`
`15 REFERENCES
`
`
`16 HOW SUPPLIED/STORAGE AND HANDLING
`
`
`16.1 Rapamune Oral Solution
`
`
`16.2 Rapamune Tablets
`
`17 PATIENT COUNSELING INFORMATION
`
`
`
`17.1 Dosage
`
`
`
`
`17.2 Skin Cancer Events
`
`
`
`17.3 Pregnancy and Lactation
`
`
`17.4 Infertility
`
`
`
`
`
`*Sections or subsections omitted from the full prescribing information are
`
`not listed.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` FULL PRESCRIBING INFORMATION: CONTENTS *
`
` WARNING: IMMUNOSUPPRESSION, USE IS NOT
`RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS
`
` 1 INDICATIONS AND USAGE
`
`
`
`
`
` 1.1 Prophylaxis of Organ Rejection in Renal Transplantation
`
` 1.2 Limitations of Use in Renal Transplantation
`
`
`
`
` 1.3 Treatment of Patients with Lymphangioleiomyomatosis
`
` 2 DOSAGE AND ADMINISTRATION
`
`
`
`
` 2.1 General Dosing Guidance for Renal Transplant Patients
`
`
` 2.2 Renal Transplant Patients at Low- to Moderate-Immunologic Risk
`
`
`
` 2.3 Renal Transplant Patients at High-Immunologic Risk
`
`
`
`
` 2.4 Dosing in Patients with Lymphangioleiomyomatosis
`
`
` 2.5 Therapeutic Drug Monitoring
`
`
`
`
` 2.6 Patients with Low Body Weight
`
`
` 2.7 Patients with Hepatic Impairment
`
` 2.8 Patients with Renal Impairment
`
`
`
` 2.9 Instructions for Dilution and Administration of Rapamune Oral
`
`
` Solution
` 3 DOSAGE FORMS AND STRENGTHS
`
`
` 3.1 Rapamune Oral Solution
`
` 3.2 Rapamune Tablets
`
`
`
` 4 CONTRAINDICATIONS
`
`
` 5 WARNINGS AND PRECAUTIONS
`
` Increased Susceptibility to Infection and the Possible
`
` 5.1
` Development of Lymphoma
`
`
`
`
`
` 5.2 Liver Transplantation – Excess Mortality, Graft Loss, and
` Hepatic Artery Thrombosis
`
`
`
`
` 5.3 Lung Transplantation – Bronchial Anastomotic Dehiscence
`
` 5.4 Hypersensitivity Reactions
`
`
`
` 5.5 Angioedema
`
`
` 5.6 Fluid Accumulation and Impairment of Wound Healing
`
`
` 5.7 Hyperlipidemia
`
`
` 5.8 Decline in Renal Function
`
`
` 5.9 Proteinuria
`
`
` 5.10 Latent Viral Infections
`
`
` 5.11 Interstitial Lung Disease/Non-Infectious Pneumonitis
`
`
` 5.12 De Novo Use Without Cyclosporine
`
`
`
` 5.13 Increased Risk of Calcineurin Inhibitor-Induced Hemolytic
`
` Uremic Syndrome/Thrombotic Thrombocytopenic
`
`
` Purpura/Thrombotic Microangiopathy
`
`
`
` 5.14 Antimicrobial Prophylaxis
`
` 5.15 Embryo-Fetal Toxicity
`
`
` 5.16 Male Infertility
`
`
`
`
` 5.17 Different Sirolimus Trough Concentrations Reported between
`
` Chromatographic and Immunoassay Methodologies
`
`
`
`
`
` 5.18 Skin Cancer Events
`
` 5.19 Immunizations
`
`
` 5.20 Interaction with Strong Inhibitors and Inducers of CYP3A4
`
` and/or P-gp
` 5.21 Cannabidiol Drug Interactions
`
`
` 6 ADVERSE REACTIONS
` 6.1 Clinical Studies Experience in Prophylaxis of Organ Rejection
`
`
`
`
` Following Renal Transplantation
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Reference ID: 5033875
`
`2
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

`FULL PRESCRIBING INFORMATION
`
`
`
`
`
` WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG
`
` TRANSPLANT PATIENTS
`
`
`•
`
`
`
` Increased susceptibility to infection and the possible development of lymphoma and other
`malignancies may result from immunosuppression
`
`
`
`
`
`
` Increased susceptibility to infection and the possible development of lymphoma may result from
`
`
` immunosuppression. Only physicians experienced in immunosuppressive therapy and management of
`renal transplant patients should use Rapamune® for prophylaxis of organ rejection in patients
`
`receiving renal transplants. Patients receiving the drug should be managed in facilities equipped and
`staffed with adequate laboratory and supportive medical resources. The physician responsible for
` maintenance therapy should have complete information requisite for the follow-up of the patient [see
`Warnings and Precautions (5.1)].
`
`
`
`
` • The safety and efficacy of Rapamune (sirolimus) as immunosuppressive therapy have not been
`
` established in liver or lung transplant patients, and therefore, such use is not recommended [see
`
`
` Warnings and Precautions (5.2, 5.3)].
` • Liver Transplantation – Excess Mortality, Graft Loss, and Hepatic Artery Thrombosis (HAT)
`
`
`
`
`
`
`
`
`
` The use of Rapamune in combination with tacrolimus was associated with excess mortality and graft
`
` loss in a study in de novo liver transplant patients. Many of these patients had evidence of infection at
`
`
`or near the time of death.
`
`
` In this and another study in de novo liver transplant patients, the use of Rapamune in combination
`
`
`
`
` with cyclosporine or tacrolimus was associated with an increase in HAT; most cases of HAT occurred
` within 30 days post-transplantation and most led to graft loss or death [see Warnings and Precautions
`
`
`
` (5.2)].
`
`
` • Lung Transplantation – Bronchial Anastomotic Dehiscence
`
`
`
`
`
`
` Cases of bronchial anastomotic dehiscence, most fatal, have been reported in de novo lung transplant
`
`
`patients when Rapamune has been used as part of an immunosuppressive regimen [see Warnings and
`Precautions (5.3)].
`
`
`
`1
`
`INDICATIONS AND USAGE
`
`
`1.1
`
`
`
` Prophylaxis of Organ Rejection in Renal Transplantation
`
`
`
` Rapamune (sirolimus) is indicated for the prophylaxis of organ rejection in patients aged 13 years or older
`
` receiving renal transplants.
`
`
`
`In patients at low-to moderate-immunologic risk, it is recommended that Rapamune be used initially in a
`
`
` regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after
`
`
` transplantation [see Dosage and Administration (2.2)].
`
` In patients at high-immunologic risk (defined as Black recipients and/or repeat renal transplant recipients who
`
`
`
`
` lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [PRA;
`
`
`
`
`Reference ID: 5033875
`
`3
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

`peak PRA level >80%]), it is recommended that Rapamune be used in combination with cyclosporine and
`corticosteroids for the first year following transplantation [see Dosage and Administration (2.3), Clinical
`
` Studies (14.3)].
`
`1.2
`
`
`
` Limitations of Use in Renal Transplantation
`
`
`
` Cyclosporine withdrawal has not been studied in patients with Banff Grade 3 acute rejection or vascular
`
`
` rejection prior to cyclosporine withdrawal, those who are dialysis-dependent, those with serum creatinine
`
` >4.5 mg/dL, Black patients, patients of multi-organ transplants, secondary transplants, or those with high levels
`
` of panel-reactive antibodies [see Clinical Studies (14.2)].
`
`
`
`In patients at high-immunologic risk, the safety and efficacy of Rapamune used in combination with
`cyclosporine and corticosteroids has not been studied beyond one year; therefore after the first 12 months
`
`
`following transplantation, any adjustments to the immunosuppressive regimen should be considered on the
`
`basis of the clinical status of the patient [see Clinical Studies (14.3)].
`
`
`
`In pediatric patients, the safety and efficacy of Rapamune have not been established in patients <13 years old,
`or in pediatric (<18 years) renal transplant patients considered at high-immunologic risk [see Adverse
`
`Reactions (6.5), Clinical Studies (14.6)].
`
`
`The safety and efficacy of de novo use of Rapamune without cyclosporine have not been established in renal
`
`
`
`
`
`transplant patients [see Warnings and Precautions (5.12)].
`
`
`
`The safety and efficacy of conversion from calcineurin inhibitors to Rapamune in maintenance renal transplant
`
`
`
`
`patients have not been established [see Clinical Studies (14.4)].
`
`
`
`1.3
`
`Treatment of Patients with Lymphangioleiomyomatosis
`
`
`
`
`Rapamune (sirolimus) is indicated for the treatment of patients with lymphangioleiomyomatosis (LAM).
`
`2
`
`DOSAGE AND ADMINISTRATION
`
`
`
`Rapamune is to be administered orally once daily, consistently with or without food [see Dosage and
`
`Administration (2.5), Clinical Pharmacology (12.3)].
`
`
`Tablets should not be crushed, chewed or split. Patients unable to take the tablets should be prescribed the
`
`solution and instructed in its use.
`
`2.1 General Dosing Guidance for Renal Transplant Patients
`
`
`
`The initial dose of Rapamune should be administered as soon as possible after transplantation. It is
`
`recommended that Rapamune be taken 4 hours after administration of cyclosporine oral solution (MODIFIED)
`
`
`
`and or/cyclosporine capsules (MODIFIED) [see Drug Interactions (7.2)].
`
`
`
`
`Frequent Rapamune dose adjustments based on non-steady-state sirolimus concentrations can lead to
`overdosing or underdosing because sirolimus has a long half-life. Once Rapamune maintenance dose is
`
`adjusted, patients should continue on the new maintenance dose for at least 7 to 14 days before further dosage
`
`
`adjustment with concentration monitoring. In most patients, dose adjustments can be based on simple
`
`proportion: new Rapamune dose = current dose x (target concentration/current concentration). A loading dose
`
`
`should be considered in addition to a new maintenance dose when it is necessary to increase sirolimus trough
`
`concentrations: Rapamune loading dose = 3 x (new maintenance dose - current maintenance dose). The
`
`
`maximum Rapamune dose administered on any day should not exceed 40 mg. If an estimated daily dose
`
`
`4
`
`
`Reference ID: 5033875
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

`exceeds 40 mg due to the addition of a loading dose, the loading dose should be administered over 2 days.
`Sirolimus trough concentrations should be monitored at least 3 to 4 days after a loading dose(s).
`
`
`
`
`Two milligrams (2 mg) of Rapamune Oral Solution have been demonstrated to be clinically equivalent to 2 mg
`
`Rapamune Tablets; hence, at this dose these two formulations are interchangeable. However, it is not known if
`
`
`
`
`higher doses of Rapamune Oral Solution are clinically equivalent to higher doses of Rapamune Tablets on a
`
`
`
`mg-to-mg basis [see Clinical Pharmacology (12.3)].
`
`
`
`2.2
`
`Renal Transplant Patients at Low- to Moderate-Immunologic Risk
`
`
`
`
`Rapamune and Cyclosporine Combination Therapy
`
`For de novo renal transplant patients, it is recommended that Rapamune Oral Solution and Tablets be used
`
`
`initially in a regimen with cyclosporine and corticosteroids. A loading dose of Rapamune equivalent to 3 times
`
`
`the maintenance dose should be given, i.e. a daily maintenance dose of 2 mg should be preceded with a loading
`dose of 6 mg. Therapeutic drug monitoring should be used to maintain sirolimus drug concentrations within the
`
`target-range [see Dosage and Administration (2.5)].
`
`
`
`Rapamune Following Cyclosporine Withdrawal
`
`
`At 2 to 4 months following transplantation, cyclosporine should be progressively discontinued over 4 to
`8 weeks, and the Rapamune dose should be adjusted to obtain sirolimus whole blood trough concentrations
`
`within the target-range [see Dosage and Administration (2.5)]. Because cyclosporine inhibits the metabolism
`
`
`and transport of sirolimus, sirolimus concentrations may decrease when cyclosporine is discontinued, unless
`
`
`the Rapamune dose is increased [see Clinical Pharmacology (12.3)].
`
`
`
`
`2.3
`
`Renal Transplant Patients at High-Immunologic Risk
`
`
`
`In patients with high-immunologic risk, it is recommended that Rapamune be used in combination with
`cyclosporine and corticosteroids for the first 12 months following transplantation [see Clinical Studies (14.3)].
`
`
`The safety and efficacy of this combination in high-immunologic risk patients has not been studied beyond the
`
`
`first 12 months. Therefore, after the first 12 months following transplantation, any adjustments to the
`
`immunosuppressive regimen should be considered on the basis of the clinical status of the patient.
`
`
`For patients receiving Rapamune with cyclosporine, Rapamune therapy should be initiated with a loading dose
`
`of up to 15 mg on day 1 post-transplantation. Beginning on day 2, an initial maintenance dose of 5 mg/day
`should be given. A trough level should be obtained between days 5 and 7, and the daily dose of Rapamune
`
`should thereafter be adjusted [see Dosage and Administration (2.5)].
`
`
`
`
`The starting dose of cyclosporine should be up to 7 mg/kg/day in divided doses and the dose should
`subsequently be adjusted to achieve target whole blood trough concentrations [see Dosage and Administration
`
`
`(2.5)]. Prednisone should be administered at a minimum of 5 mg/day.
`
`
`Antibody induction therapy may be used.
`
`
`
`2.4
`
`Dosing in Patients with Lymphangioleiomyomatosis
`
`
`
`
`
`For patients with lymphangioleiomyomatosis, the initial Rapamune dose should be 2 mg/day. Sirolimus whole
`
`
`blood trough concentrations should be measured in 10-20 days, with dosage adjustment to maintain
`concentrations between 5-15 ng/mL [see Dosage and Administration (2.5)].
`
`
`
`
`Reference ID: 5033875
`
`5
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

` In most patients, dose adjustments can be based on simple proportion: new Rapamune dose = current dose x
`
`
`
`
`
` (target concentration/current concentration). Frequent Rapamune dose adjustments based on non-steady-state
` sirolimus concentrations can lead to overdosing or under dosing because sirolimus has a long half-life. Once
`
`
`
`
` Rapamune maintenance dose is adjusted, patients should continue on the new maintenance dose for at least 7 to
`14 days before further dosage adjustment with concentration monitoring. Once a stable dose is achieved,
`
`therapeutic drug monitoring should be performed at least every three months.
`
`
`2.5
`
`
`Therapeutic Drug Monitoring
`
`
`Monitoring of sirolimus trough concentrations is recommended for all patients, especially in those patients
`
`likely to have altered drug metabolism, in patients ≥ 13 years who weigh less than 40 kg, in patients with
`hepatic impairment, when a change in the Rapamune dosage form is made, and during concurrent
`
`administration of strong CYP3A4 inducers and inhibitors [see Warnings and Precautions (5.20, 5.21), Drug
`
`
`
`Interactions (7)].
`
`
`Therapeutic drug monitoring should not be the sole basis for adjusting Rapamune therapy. Careful attention
`should be made to clinical signs/symptoms, tissue biopsy findings, and laboratory parameters.
`
`
`
`When used in combination with cyclosporine, sirolimus trough concentrations should be maintained within the
`
`target-range [see Clinical Studies (14), Clinical Pharmacology (12.3)]. Following cyclosporine withdrawal in
`
`transplant patients at low- to moderate-immunologic risk, the target sirolimus trough concentrations should be
`
`
`16 to 24 ng/mL for the first year following transplantation. Thereafter, the target sirolimus concentrations
`
`should be 12 to 20 ng/mL.
`
`
`
`The above recommended 24-hour trough concentration ranges for sirolimus are based on chromatographic
`
`
`
`methods. Currently in clinical practice, sirolimus whole blood concentrations are being measured by both
`chromatographic and immunoassay methodologies. Because the measured sirolimus whole blood
`concentrations depend on the type of assay used, the concentrations obtained by these different methodologies
`
`are not interchangeable [see Warnings and Precautions (5.17), Clinical Pharmacology (12.3)]. Adjustments to
`
`
`
`the targeted range should be made according to the assay utilized to determine sirolimus trough
`
`concentrations. Since results are assay and laboratory dependent, and the results may change over time,
`adjustments to the targeted therapeutic range must be made with a detailed knowledge of the site-specific
`assay used. Therefore, communication should be maintained with the laboratory performing the assay. A
`
`
`discussion of different assay methods is contained in Clinical Therapeutics, Volume 22, Supplement B,
`April 2000 [see References (15)].
`
`
`
`
`2.6
`
`
`Patients with Low Body Weight
`
`
`The initial dosage in patients ≥13 years who weigh less than 40 kg should be adjusted, based on body surface
`
`
`area, to 1 mg/m2/day. The loading dose should be 3 mg/m2.
`
`
`
`
`2.7
`
`
`Patients with Hepatic Impairment
`
`
`
`It is recommended that the maintenance dose of Rapamune be reduced by approximately one third in patients
`
`with mild or moderate hepatic impairment and by approximately one half in patients with severe hepatic
`
`
`impairment. It is not necessary to modify the Rapamune loading dose [see Use in Specific Populations (8.6),
`
`Clinical Pharmacology (12.3)].
`
`
`Reference ID: 5033875
`
`6
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

`
`
` 2.8
`
`
`
` Patients with Renal Impairment
`
`
`
` Dosage adjustment is not needed in patients with impaired renal function [see Use in Specific Populations
`
` (8.7)].
`
`
`
`
`
` 2.9
`
`
`
` Instructions for Dilution and Administration of Rapamune Oral Solution
`
`The amber oral dose syringe should be used to withdraw the prescribed amount of Rapamune Oral Solution
`from the bottle. Empty the correct amount of Rapamune from the syringe into only a glass or plastic container
`
`holding at least two (2) ounces (1/4 cup, 60 mL) of water or orange juice. No other liquids, including grapefruit
`
`
`juice, should be used for dilution [see Drug Interactions (7.3), Clinical Pharmacology (12.3)]. Stir vigorously
`
`and drink at once. Refill the container with an additional volume [minimum of four (4) ounces (1/2 cup,
`
`
`
`120 mL)] of water or orange juice, stir vigorously, and drink at once.
`
`
`
`Rapamune Oral Solution contains polysorbate 80, which is known to increase the rate of
`
`di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC). This should be considered
`
`during the preparation and administration of Rapamune Oral Solution. It is important that these
`
`
`recommendations be followed closely.
`
`
`
`3
`
`
`DOSAGE FORMS AND STRENGTHS
`
`
`3.1
`
`
`Rapamune Oral Solution
`
`
`
` • 60 mg per 60 mL in amber glass bottle.
`
`
`
`
`
`
` 3.2 Rapamune Tablets
`
`
`
`
` • 0.5 mg, tan, triangular-shaped tablets marked “RAPAMUNE 0.5 mg” on one side.
`
` • 1 mg, white, triangular-shaped tablets marked “RAPAMUNE 1 mg” on one side.
`
`
` • 2 mg, yellow-to-beige triangular-shaped tablets marked “RAPAMUNE 2 mg” on one side.
`
`
`
`
`
`
`
` 4
`
`
`
` CONTRAINDICATIONS
`
`
`
` Rapamune is contraindicated in patients with a hypersensitivity to Rapamune [see Warnings and Precautions
`
` (5.4)].
`
`
`
`
`
` 5 WARNINGS AND PRECAUTIONS
`
`
`
`
`
` 5.1
`
`
`
` Increased Susceptibility to Infection and the Possible Development of Lymphoma
`
`Increased susceptibility to infection and the possible development of lymphoma and other malignancies,
`
`particularly of the skin, may result from immunosuppression. The rates of lymphoma/lymphoproliferative
`
`
`disease observed in Studies 1 and 2 were 0.7-3.2% (for Rapamune-treated patients) versus 0.6-0.8%
`
`
`
`(azathioprine and placebo control) [see Adverse Reactions (6.1) and (6.2)]. Oversuppression of the immune
`
`
`
`system can also increase susceptibility to infection, including opportunistic infections such as tuberculosis, fatal
`infections, and sepsis. Only physicians experienced in immunosuppressive therapy and management of organ
`
`
`
`transplant patients should use Rapamune for prophylaxis of organ rejection in patients receiving renal
`
`transplants. Patients receiving the drug should be managed in facilities equipped and staffed with adequate
`
`
`laboratory and supportive medical resources. The physician responsible for maintenance therapy should have
`
`complete information requisite for the follow-up of the patient.
`
`
`Reference ID: 5033875
`
`7
`
`This label may not be the latest approved by FDA.
`For current labeling information, please visit https://www.fda.gov/drugsatfda
`
`

`

`5.2
`
`
`Liver Transplantation – Excess Mortality, Graft Loss, and Hepatic Artery Thrombosis
`
`
`
`The safety and efficacy of Rapamune as immunosuppressive therapy have not been established in liver
`
`
`transplant patients; therefore, such use is not recommended. The use of Rapamune has been associated with
`
`adverse outcomes in patients following liver transplantation, including excess mortality, graft loss and hepatic
`artery thrombosis (HAT).
`
`
`
`In a study in de novo liver transplant patients, the use of Rapamune in combination with tacrolimus was
`
`
`
`associated with excess mortality and graft loss (22% in combination versus 9% on tacrolimus alone). Many of
`
`
`these patients had evidence of infection at or near the time of death.
`
`
`
`In this and another study in de novo liver transplant patients, the use of Rapamune in combination with
`
`cyclosporine or tacrolimus was associated with an increase in HAT (7% in combination versus 2% in the
`
`control arm); most cases of HAT occurred within 30 days post-transplantation, and most led to graft loss or
`
`
`death.
`
`
`In a clinical study in stable liver transplant patients 6-144 months post-liver transplantation and receiving a
`
`CNI-based regimen, an increased number of deaths was observed in the group converted to a Rapamune-based
`
`regimen compared to the group who was continued on a CNI-based regimen, although the difference was not
`
`
`statistically significant (3.8% versus 1.4%) [see Clinical Studies (14.5)].
`
`
`
`
`5.3
`
`
`Lung Transplantation – Bronchial Anastomotic Dehiscence
`
`
`
`
`Cases of bronchial anastomotic dehiscence, most fatal, have been reported in de novo lung transplant patients
`
`
`
`when Rapamune has been used as part of an immunosuppressive regimen.
`
`
`
`The safety and efficacy of Rapamune as immunosuppressive therapy have not been established in lung
`
`transplant patients; therefore, such use is not recommended.
`
`
`5.4
`
`
`Hypersensitivity Reactions
`
`
`Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, angioedema, exfoliative dermatitis
`
`
`and hypersensitivity vasculitis, have been associated with the administration of Rapamune [see Adverse
`
`
`Reactions (6.7)].
`
`
`5.5
`
`
`Angioedema
`
`
`Rapamune has been associated with the development of angioedema. The concomitant use of Rapamune with
`
`other drugs known to cause angioedema, such as angiotensin-converting enzyme (ACE) inhibitors, may
`
`
`increase the risk of developing angioedema. Elevated sirolimus levels (with/without concomitant ACE
`
`
`
`
`
`inhibitors) may also potentiate angioedema [see Drug Interactions (7.2)]. In some cases, the angioedema has
`
`
`
`resolved upon discontinuation or dose reduction of Rapamune.
`
`
`
`5.6
`
`
`Fluid Accumulation and Impairment of Wound Healing
`
`
`There have been reports of impaired or delayed wound healing in patients receiving Rapamune, including
`lymphocele and wound dehiscence [see Adverse Reactions (6.1)]. Mammalian target of rapamycin (mTOR)
`
`
`
`
`
`inhibitors such as sirolimus have been shown in vitro to inhibit production of certain growth factors that may
`
`
`affect angiogenesis, fibroblast proliferation, and vascular permeability. Lymphocele, a known surgical
`
`complication of renal transplantation,